# Hour 11: 11:00-11:59 - Peak Continues

Released on 23 March 2026 | CEO Kevin Kawchak | ChemicalQDevice

## Hour Summary

Hour 11 sustains peak-period throughput with 13 new patient arrivals
(PAT-ODMND-0073 through PAT-ODMND-0085), maintaining approximately 28
concurrent patients on-site. All 10 robot types are engaged during this
hour, with overall robot utilization reaching approximately 65%. A Grade 2
adverse event occurs with PAT-ODMND-0081 during steerable needle advancement
at 11:45 and is managed successfully with additional local anesthetic. A
major surgical case (P0044) completes at 11:00 after 180 minutes, while
P0065 surgery continues from the prior hour. One PSL dimension adjustment is
recorded: Needle-Placement Dimension C increases by +0.1 based on consistent
accuracy across multiple procedures. Site PSL advances to 64.7.

## Site Status at 11:00

- Total patients on-site: approximately 28 (15 continuing, 13 new arrivals)
- Active procedures at hour start: 1 (P0065 surgery ongoing via SURG-02)
- Robots in active mode: 19
- Robots in standby mode: 8
- Robots in cleaning/transition: 2
- Robots in maintenance: 0
- Queue length: 2 (adult waiting)
- Site safety officer on duty: SSO-D2 (day shift)

## New Patient Arrivals

| Patient ID | Time | Age | Sex | Cancer Type | Stage | ECOG | Robot Assigned |
|-----------|------|-----|-----|-------------|-------|------|---------------|
| PAT-ODMND-0073 | 11:00 | 64 | M | NSCLC adenocarcinoma | IIIA | 1 | TRACK-02 |
| PAT-ODMND-0074 | 11:05 | 45 | F | Forearm sarcoma | II | 0 | COBOT-03 |
| PAT-ODMND-0075 | 11:08 | 69 | M | Meningioma | I | 0 | RTPOS-03 |
| PAT-ODMND-0076 | 11:12 | 8 | F | Pediatric ALL | - | 1 | COMPN-04 |
| PAT-ODMND-0077 | 11:16 | 52 | M | Parotid tumor | II | 0 | NEEDLE-02 |
| PAT-ODMND-0078 | 11:20 | 60 | F | HCC | II | 1 | IMAGE-04 |
| PAT-ODMND-0079 | 11:24 | 57 | M | Mediastinal tumor | III | 1 | SURG-02 |
| PAT-ODMND-0080 | 11:28 | 11 | F | Pediatric osteosarcoma | - | 1 | HUMAN-03, REHAB-01 |
| PAT-ODMND-0081 | 11:32 | 76 | M | Liver metastases | IV | 2 | STEER-02 |
| PAT-ODMND-0082 | 11:36 | 48 | F | NSCLC squamous | IIIB | 1 | TRACK-03 |
| PAT-ODMND-0083 | 11:40 | 36 | M | Forearm sarcoma | I | 0 | COBOT-04 |
| PAT-ODMND-0084 | 11:44 | 72 | F | Brain metastases | IV | 1 | RTPOS-01 |
| PAT-ODMND-0085 | 11:48 | 65 | M | Femur osteosarcoma | - | 2 | REHAB-02 |

## Completed Procedures This Hour

### P0044 Surgery Completion (11:00)
- Patient: PAT-ODMND-0044
- Robot: SURG-01
- Procedure: Tumor resection (180 minutes total, started 08:00)
- Outcome: Successful. Estimated blood loss 210 mL.
- Post-op: Patient transferred to Recovery Bay 4 for monitoring.
- Digital twin: Surgical model finalized with resection margins confirmed.

## Active Procedures This Hour

### RT Motion-Tracking Session - PAT-ODMND-0073 (11:08-11:26)
- Robot: TRACK-02 (Radiotherapy Vault 2)
- Procedure: NSCLC adenocarcinoma, Stage IIIA, RT fraction delivery
- Duration: 18 minutes (calibration 2 min, treatment 14 min, exit 2 min)
- Beam gating efficiency: 93.8%
- Breathing amplitude: 3.9 mm (within tolerance after coaching)
- Marker displacement: 1.7 mm average
- Treatment interruptions: 0
- Dose delivered: 2.0 Gy
- Outcome: Successful completion. Full dose delivered.

Minute-by-minute summary:
- 11:08 - Patient positioned on couch, marker block placed
- 11:09 - Calibration complete, breathing baseline established
- 11:10 - Beam-on, field 1. Gating active.
- 11:14 - Field 1 complete (1.0 Gy delivered)
- 11:15 - Gantry rotation to field 2
- 11:16 - Beam-on, field 2
- 11:20 - Field 2 complete (0.6 Gy delivered)
- 11:21 - Gantry rotation to field 3
- 11:22 - Beam-on, field 3
- 11:24 - Field 3 complete (0.4 Gy delivered). Total: 2.0 Gy.
- 11:25 - Marker block removed, patient assisted to seated position
- 11:26 - Patient exits vault. Procedure complete.

### Cobot Biopsy - PAT-ODMND-0074 (11:13-11:28)
- Robot: COBOT-03 (Biopsy Station 3)
- Procedure: Forearm sarcoma core needle biopsy, Stage II
- Duration: 15 minutes
- Force applied: 2.4 N (within 1-4 N range)
- Tissue cores obtained: 4 (target: 3-5)
- Bleeding: Minimal, controlled with direct pressure
- Outcome: Successful. Specimens sent to pathology.

### RT Positioning - PAT-ODMND-0075 (11:16-11:38)
- Robot: RTPOS-03 (Radiotherapy Vault 3)
- Procedure: Meningioma RT positioning and treatment, Grade I
- Duration: 22 minutes (mask fitting 5 min, positioning 5 min, treatment 10 min, exit 2 min)
- Mask registration accuracy: 0.4 mm (tolerance: less than 1.0 mm)
- 6-DOF couch alignment: All axes within 0.3 mm / 0.2 degrees
- Dose delivered: 1.8 Gy (stereotactic fractionation)
- Outcome: Successful. Precise cranial alignment maintained throughout.

### Social Companion Session - PAT-ODMND-0076 (11:15-11:55)
- Robot: COMPN-04 (Pediatric Play Area 4)
- Procedure: Companion support for 8-year-old female with ALL
- Duration: 40 minutes (ongoing at hour end)
- Interaction mode: Therapeutic play, anxiety assessment
- Anxiety score: Initial 6/10, reduced to 3/10 by 11:35
- Vital signs: Monitored via room sensors. HR 92 bpm (age-appropriate).
- Outcome: Ongoing. Patient engaged in guided play activities.

### Needle-Placement - PAT-ODMND-0077 (11:24-11:42)
- Robot: NEEDLE-02 (CT Suite 2)
- Procedure: CT-guided fine needle aspiration of parotid tumor, Stage II
- Duration: 18 minutes
- CT guidance: Real-time fluoroscopic overlay
- Needle trajectory accuracy: 1.1 mm from planned path
- Tissue sample quality: Adequate for cytology
- Complications: None
- Outcome: Successful. Sample sent to pathology.

### Imaging Assessment - PAT-ODMND-0078 (11:28-11:41)
- Robot: IMAGE-04 (Imaging Bay 4)
- Procedure: Robotic ultrasound liver assessment for HCC, Stage II
- Duration: 13 minutes
- Probe pressure: 1.9 N (within 1-3 N range)
- Image quality score: 8.4/10
- Primary tumor measurement: 31 mm x 25 mm
- Scan coverage: 94%
- Motion artifacts: 1 (auto-compensated)
- Outcome: Successful. Images uploaded to DICOM server for treatment planning.

### Surgery - PAT-ODMND-0079 (11:35-ongoing)
- Robot: SURG-02 (Surgical Suite 2)
- Procedure: Mediastinal tumor debulking, Stage III
- Pre-op: Pembrolizumab administered per IND protocol (see Investigational Drug section)
- Anesthesia: General (induction 11:30)
- Status at hour end: Surgery in progress (25 minutes elapsed)
- Blood loss at 11:59: 85 mL
- AI model inference: Real-time tissue classification active
- Digital twin: Intraoperative model updating continuously

### Humanoid Therapy - PAT-ODMND-0080 (11:36-11:56)
- Robot: HUMAN-03 (Humanoid Therapy Room 3)
- Procedure: Guided mobility assessment for 11-year-old female with osteosarcoma
- Duration: 20 minutes
- Interaction: Walking pattern analysis, joint range measurement
- Patient engagement: Cooperative, moderate pain reported in left leg
- Outcome: Assessment complete. Transition to REHAB-01 at 11:56.

### Rehabilitation - PAT-ODMND-0080 (11:56-ongoing)
- Robot: REHAB-01 (Rehabilitation Bay 1)
- Procedure: Lower extremity exoskeleton-assisted gait training
- Session: Initial evaluation session
- Status at hour end: In progress (3 minutes elapsed)
- Gait speed: 0.4 m/s initial measurement
- Weight support: 40% body weight offloaded

### Steerable Needle - PAT-ODMND-0081 (11:40-11:58)
- Robot: STEER-02 (Ablation Suite 2)
- Procedure: Steerable needle ablation planning for liver metastases, Stage IV
- Duration: 18 minutes
- ADVERSE EVENT at 11:45: Patient reports pain score 7/10 during needle
  advancement (see Adverse Events section). Procedure paused. Additional
  local anesthetic (lidocaine bolus) administered. Pain reduced to 3/10.
  Procedure resumed at 11:50 and completed successfully.
- Needle tip accuracy: 1.3 mm from target
- Ablation zone coverage: 95% of planned volume
- Outcome: Completed with managed adverse event.

### RT Motion-Tracking Session - PAT-ODMND-0082 (11:44-11:59)
- Robot: TRACK-03 (Radiotherapy Vault 1)
- Procedure: NSCLC squamous cell carcinoma, Stage IIIB, RT fraction
- Status at hour end: Treatment in progress (15 minutes elapsed)
- Beam gating efficiency: 94.1% (partial measurement)
- Breathing amplitude: 4.3 mm
- Dose delivered by 11:59: 1.6 Gy of planned 2.0 Gy

### Cobot Biopsy - PAT-ODMND-0083 (11:48-ongoing)
- Robot: COBOT-04 (Biopsy Station 4)
- Procedure: Forearm sarcoma core needle biopsy, Stage I
- Status at hour end: In progress (11 minutes elapsed)
- Force applied: 2.2 N (within tolerance)

### RT Positioning - PAT-ODMND-0084 (11:52-ongoing)
- Robot: RTPOS-01 (Radiotherapy Vault 1)
- Procedure: Brain metastases stereotactic RT positioning, Stage IV
- Status at hour end: Mask fitting in progress (7 minutes elapsed)
- Mask registration: Pending completion

### Rehabilitation - PAT-ODMND-0085 (11:56-ongoing)
- Robot: REHAB-02 (Rehabilitation Bay 2)
- Procedure: Lower extremity rehabilitation for femur osteosarcoma
- Status at hour end: Initial assessment (3 minutes elapsed)
- Gait evaluation: Antalgic gait pattern noted, baseline measurements recording

## Ongoing Surgery from Prior Hour

### P0065 Surgery (started approximately 10:40)
- Robot: SURG-01 (Surgical Suite 1)
- Status: Surgery in progress throughout hour 11
- Estimated completion: Hour 12
- Blood loss at 11:59: 165 mL
- Procedure status: Within expected parameters

## Patient Departures This Hour

| Patient ID | Time | Outcome | Notes |
|-----------|------|---------|-------|
| PAT-ODMND-0044 | 11:00 | Procedure complete | Transferred to recovery bay |
| PAT-ODMND-0073 | 11:30 | Discharged | RT fraction complete, no complications |
| PAT-ODMND-0074 | 11:32 | Discharged | Biopsy complete, hemostasis confirmed |
| PAT-ODMND-0075 | 11:42 | Discharged | RT complete, no complications |
| PAT-ODMND-0077 | 11:48 | Discharged | FNA complete, no complications |
| PAT-ODMND-0078 | 11:46 | Discharged | Imaging complete |
| Multiple earlier patients | Various | Discharged | Scheduled post-procedure discharges |

## Adverse Events

### AE-011-001: Grade 2 Procedural Pain (PAT-ODMND-0081)
- Patient: PAT-ODMND-0081 (76M, liver metastases, Stage IV, ECOG 2)
- Robot: STEER-02 (Steerable Needle, Ablation Suite 2)
- Time of onset: 11:45
- Description: Patient reports pain score 7/10 during steerable needle
  advancement through hepatic parenchyma toward metastatic lesion in
  segment VII. Pain localized to right upper quadrant with radiation to
  right shoulder (referred diaphragmatic irritation pattern).
- CTCAE Grade: 2 (moderate; limiting instrumental ADL)
- Immediate action: Procedure paused. Robot needle advancement halted at
  current position (needle tip stable, no displacement). Attending
  physician notified. Additional lidocaine bolus administered (see
  Investigational Drug section). Patient reassessed at 11:48.
- Resolution: Pain reduced to 3/10 within 3 minutes of lidocaine
  administration. Patient confirmed comfort to continue. Procedure resumed
  at 11:50 and completed successfully at 11:58.
- Causality assessment: Related to procedure (needle traversal of hepatic
  capsule); robot performance within specification (needle tip accuracy
  1.3 mm). Not attributed to robot malfunction.
- Reporting: Documented per 21 CFR 312.32 safety reporting requirements.
  Entered in trial safety database. Principal Investigator notified.
  Not a Serious Adverse Event (does not meet SAE criteria per 21 CFR
  312.32(a) as it did not result in hospitalization, was not life-
  threatening, and resolved with intervention).
- Follow-up: Patient monitored for 30 minutes post-procedure. Discharged
  with pain management instructions. 24-hour follow-up call scheduled.

## Investigational Drug Administrations

### PAT-ODMND-0079: Pembrolizumab (Pre-operative)
- Drug: Pembrolizumab 200 mg IV
- IND status: Administered under IND protocol for neoadjuvant
  immunotherapy in mediastinal tumors
- Administration time: 11:28 (prior to surgical induction at 11:30)
- Route: Intravenous infusion over 30 minutes (started 10:58, completed 11:28)
- Adverse reactions during infusion: None observed
- Pharmacist verification: Confirmed per 21 CFR 312.61
- Chain of custody: Pharmacy to infusion suite, double-verified
- Documentation: Recorded in case report form per ICH E6(R3) Section 4.2.1

### PAT-ODMND-0081: Lidocaine Bolus (Pain Management)
- Drug: Lidocaine 1% local anesthetic, 10 mL subcutaneous/intercostal
- Administration time: 11:46
- Indication: Grade 2 procedural pain during steerable needle advancement
- Route: Local infiltration at needle entry site and intercostal nerve block
- Response: Pain score reduced from 7/10 to 3/10 within 3 minutes
- Classification: Concomitant medication (standard-of-care pain management),
  not an investigational product
- Documentation: Recorded per 21 CFR 312.62 investigator recordkeeping

## Site Utilization

- Overall robot utilization: approximately 65% (19 of 29 robots active at peak)
- Queue lengths: 2 patients in adult waiting (average), 1 in pediatric waiting
- Average wait time: 6 minutes (range 3-8 minutes)
- Robot cleaning cycles: 8 completed during hour
- Concurrent patients at peak: 28

## Regulatory Compliance Notes

### ICH E6(R3) - Adaption
- Section 1.1.1: All procedures conducted under GCP principles with
  identical safety standards maintained during peak operations. Increased
  patient volume did not compromise protocol adherence.
- Section 2.9.1: Complete audit trails maintained for all 13 new patient
  encounters including robot telemetry, vital signs, procedure timestamps,
  and outcome data with synchronized UTC timestamps.
- Section 2.10: Adverse event (AE-011-001) detected, assessed, and
  documented per protocol. CTCAE grading applied. Causality assessment
  completed within 60 minutes of onset.
- Section 4.2.1: Data capture maintained across all concurrent procedures.
  Digital twin models updated for surgical, RT, and interventional cases.
  FHIR-compliant patient data exchange verified for all 13 arrivals.
- Appendix C: Documentation completeness verified for all procedures
  including robot interaction logs, AI model inference records, and
  sensor telemetry archives.

### 21 CFR Part 50 - Adaption
- Section 50.25: All 13 new patients had completed informed consent
  including Physical AI system disclosure, robot type identification,
  USL readiness scores for assigned platforms, PSL performance context,
  and right to non-Physical AI alternatives. Pediatric patients
  (PAT-ODMND-0076 age 8, PAT-ODMND-0080 age 11) had parental/guardian
  consent with age-appropriate assent documentation.
- Section 50.30: Pre-procedure safety matrix completed for all procedures:
  patient identity confirmed biometrically, clinical data accessed via
  FHIR, robot readiness verified, environmental checks passed.

### 21 CFR Part 312 - Adaption
- Section 312.32: Adverse event AE-011-001 (Grade 2 procedural pain)
  documented and reported per protocol. Not classified as SAE. Safety
  monitoring board notification within 24 hours per reporting schedule.
- Section 312.61: Pembrolizumab administered to PAT-ODMND-0079 under IND
  with pharmacy verification and chain-of-custody documentation.
- Section 312.62: Investigator recordkeeping maintained for all patients
  including Physical AI system interaction logs, vital sign records,
  procedure outcomes, and concomitant medication documentation (lidocaine
  for PAT-ODMND-0081).

## Complementary Framework References

The Unification Standard Level (USL) framework (Kawchak, 2026;
DOI: 10.5281/zenodo.18778220) provides complementary robot technical
interoperability scoring. Steerable Needle Robot STEER-02 demonstrated
maintained positioning accuracy (1.3 mm) during the adverse event pause,
reflecting robust USL-consistent mechanical stability. The surgical robots
SURG-01 and SURG-02 operating concurrently reflect multi-instance
orchestration capabilities evaluated in USL Dimension 3 (cross-robot
sharing). See physical-ai-oncology-trials/unification/usl/paper/usl_oncology_trials.tex.

The single-patient cancer journey framework (Kawchak, 2026;
DOI: 10.5281/zenodo.19119939) demonstrated autonomous Physical AI trial
orchestration for an individual patient. PAT-ODMND-0080's multi-robot
journey (HUMAN-03 assessment followed by REHAB-01 gait training) represents
Stage 4/5-equivalent care coordination within the multi-patient on-demand
context, demonstrating seamless handoff between robot types as described in
the patient journey framework.
See physical-ai-oncology-trials/patient-journey/paper/patient_journey_paper.tex.
